Results 241 to 250 of about 3,831,493 (359)

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy

open access: yesAnnals of Neurology, EarlyView.
Objective Exenatide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has neuroprotective effects in preclinical models of multiple system atrophy (MSA). We investigated these effects in a proof‐of‐concept clinical trial. Methods In this single‐center, randomized, open label trial, participants with MSA were randomly assigned (1:1) to receive ...
Nirosen Vijiaratnam   +29 more
wiley   +1 more source

Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective A better understanding of factors associated with multiple sclerosis (MS) disease activity and disability is needed. Given the strong link between comorbid depression and MS disease activity and disability, we aimed to determine whether the depression genetic burden, as modelled using its polygenic score, is associated with MS disease ...
Ali Manouchehrinia   +24 more
wiley   +1 more source

Symptom Attributions in Illness Anxiety Disorder. [PDF]

open access: yesJ Clin Psychol
Holden ML   +6 more
europepmc   +1 more source

TARDBP (TDP‐43) Knock‐in Zebrafish Display a Late‐Onset Motor Phenotype and Loss of Large Spinal Cord Motor Neurons

open access: yesAnnals of Neurology, EarlyView.
Objective Mutations in TARDBP (encoding TDP‐43) are associated with the neurodegenerative disease amyotrophic lateral sclerosis (ALS) and include familial missense mutations where there are a lack of models and mechanisms examining how they are pathogenic.
Ziyaan A. Harji   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy